Activity Information

The Pediatric Rheumatology Course 2023 features key updates covering a wide range of pediatric rheumatology diseases. This course is well-suited for anyone needing an update in the field of pediatric rheumatology or simply seeking an activity available at your convenience.

The Pediatric Rheumatology Course was developed from sessions that took place during the ACR’s Pediatric Rheumatology Symposium, Education Exchange, and ACR Convergence, the ACR’s annual meeting. Six individual lectures range in duration from 30 minutes to two hours and include a Q&A session. Topics from the 2023 activity include:

• Vasculitis
• Difficult to Manage JIA: What to do after in Juvenile Idiopathic Arthritis
• Calcinosis in Juvenile Dermatomyositis
• Current Approaches to Chronic Non-bacterial Osteomyelitis Care 
• Novel Approaches: Enhancing Mental Health in Children
• Kawasaki Disease Guidelines

Earn up to 6.75 ABIM MOC points and 6.75 AMA PRA Category 1 Credit(s)™ with a passing score of 70% or higher.

Target Audience

Rheumatologists, pediatric rheumatologists, pediatricians, physicians, and healthcare providers who care for pediatric patients with rheumatic diseases.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

• Review seminal work on calcinosis development.
• Analyze the strengths and limitations of different assessments of calcinosis, including imaging techniques.
• Review the evidence to support treatment decisions for calcinosis.
• List the multiple ways in which chronic nonbacterial osteomyelitis (CNO) may present in current pediatric rheumatology practice.
• Describe the role of whole body MRI in the detection and monitoring of CNO, relative to other imaging modalities.
• Describe the medications currently used for CNO and the available evidence supporting their use.
• Discuss the management of refractory non-systemic juvenile idiopathic arthritis (JIA) and uveitis.
• Discuss withdrawal of DMARDs for well-controlled, non-systemic JIA and uveitis, including timing, strategy, monitoring, and approach to flare.
• Review the 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease.
• Recognize mental health impact, current care practices, and gaps.
• Identify clinical practice change for optimized mental healthcare.
• Identify factors contributing to the relationship between rheumatologic disease and mental health in affected youth.
• Review recent advances in imaging of Takayasu arteritis (TAK) and how/when to use information from serial imaging to tailor treatments.
• Demonstrate which biologics have been studied in TAK and how can this be applied to the pediatric population.
• Review advances in vessel wall imaging in childhood primary angiitis of the central nervous system (cPACNS).
• Discuss treatment protocols in cPACNS.

Registration Fees

ACR/ARP Member: $299
ACR/ARP Potential Member: $499

CME and MOC Information

Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The ACR designates this enduring activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pediatrics (ABP)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 6.75 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

By completing this activity you provide the ACR permission to share completion data with the ACCME and the certifying board(s).

Faculty and Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.  Examples can be found at Accreditation Council for Continuing Medical Education - ACCME .

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

1. Advisor or review panel member
2. Consultant
   
3. Employee
   
4. Officer or Board Member
   
5. Grant/research support
   
6. Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
   
7. Independent contractor
   
8. Executive role and/or ownership interest
   
9. Royalties and/or patent beneficiary
   
10. Intellectual property/patents
    
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
    
12. Private investigator
    
13. Expert witness
    
14. Equity interest
    
15. Other: specify details
    

Faculty

• Hedrich, Christian, MD, PhD - Novartis, 2 (Terminated, August 31, 2021)
• Ferguson, Polly, MD - No financial relationships with ineligible companies to disclose
• Doria, Andrea, MD, PhD, MSc, MBA - Baxalta-Shire, 5 (Ongoing); Novo Nordisk, 5 (Ongoing); Terry Fox Foundation, 5 (Ongoing)
• Lood, Christian, PhD - No financial relationships with ineligible companies to disclose
• Schiffenbauer, Adam, MD - AstraZeneca, 5 (Ongoing); Hope Pharmaceuticals, 5 (Ongoing)
• Pilkington, Clarissa, MBBS, BSc, FRCPC, FRCP - No financial relationships with ineligible companies to disclose
• Melissa Mannion, MD - No financial relationships with ineligible companies to disclose
• Joost Swart, MD, PhD - No financial relationships with ineligible companies to disclose
• Ashley M. Cooper, MD - No financial relationships with ineligible companies to disclose
• Mark Gorelik, MD - No financial relationships with ineligible companies to disclose
• Knight, Andrea, MD, MSCE - Pfizer, 6 (Ongoing)
• Vora, Sheetal, MD, MS - No financial relationships with ineligible companies to disclose
• Leever, Alana, PhD - No financial relationships with ineligible companies to disclose
• Edison, Suzanne, MA, MFA - No financial relationships with ineligible companies to disclose
• Susanne (Susa) Benseler, MD, PhD, FRCPC -  No financial relationships with ineligible companies to disclose
• Ozen, Seza, MD, MSc - No financial relationships with ineligible companies to disclose

• Kaitlin Quinn, MD;MHS - No financial relationships with ineligible companies to disclose

Content Bundle Planning Team Members

The following Content Bundle Planning Team members have no relevant financial relationship(s) with ineligible companies to disclose.

• Adena Batterman, LCSW, MSW
• Belina Yi, D.O.
• Annelle Reed, MSN, CPNP
• Kai Sun, MD, MS
• Dawn Wahezi, MD, MS
• Rebecca Manno, MD, MHS
• Maura Daly Iversen, PT, DPT, SD, MPH, FNAP, FAPTA
• Susan Farrow
• Lawrence Cunningham
• Carlos Ferreira, MA
• Sharon Ross

The following planning committee members have relevant financial relationship(s) with ineligible companies to disclose.

• Kaveh Ardalan, MD, MS – Cabaletta Bio, Inc. ¹; Cure JM Foundation⁵
• Susan Shenoi, MBBS, MS, RhMSUS – Pfizer²; Cabaletta Bio, Inc²; Novartis²; Amgen²
• Lesley Ann Saketkoo, MD, MPH - Argenx^1,5; Atyr^1,5; Boehringer Ingelheim^1,5; Horizon^1,5; Janssen^1,5; Kadmon^1,5; Kinevant^1,5; Kyverna^1,5; Mallinckrodt^1,5; Novartis^1,5; UCB^1,5

*All of the relevant financial relationships listed for these individuals have been mitigated.

Corporate Support 

No grant support funded at this time. 

Online Activity Refund Policy

• Requests for cancellations and refunds must be received in writing to education@rheumatology.org within 24 hours of the online activity enrollment date.
• Completed online activities are not eligible for a refund. 
• Refunds will be subject to an administration fee per person and per activity: 15% for members; 30% for potential members.
• Canceled online activities are nontransferable.